Key facts
- Enlaza Therapeutics’s last known valuation is $295.0M (Sep 2025).
- It has raised $176.0M across 3 recorded rounds; the latest was Early Stage VC ($15.0M) in Aug 2025.
- Notable investors include Lightspeed Venture Partners, Alexandria Venture Investments, Samsara BioCapital, Pfizer Ventures, Frazier Healthcare Partners — 13 tracked in total.
- Enlaza Therapeutics has filed 8 Form Ds with the SEC since 2021, most recently Sep 2025 ($15.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Enlaza Therapeutics
Funding rounds
3 roundsAbout Enlaza Therapeutics
Developer of covalent protein therapeutics intended to deliver efficacious and safer treatments. The company offers a novel synthetic biology platform that uses covalent bonds to lock onto a target protein to provide sustained occupancy and prolonged biologic effect with minimal systemic exposure, enabling healthcare professionals to treat various diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 55
- Website
- enlazatx.com/
- Ownership
- Privately Held (backing)
Enlaza Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enlaza Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enlaza Therapeutics in its N-PORT filings yet. We sweep new filings monthly.